Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VTYX |
---|---|---|
09:32 ET | 3441 | 2.1 |
09:34 ET | 5636 | 2.08 |
09:36 ET | 200 | 2.08 |
09:38 ET | 864 | 2.089 |
09:39 ET | 100 | 2.08 |
09:41 ET | 3439 | 2.08 |
09:43 ET | 8290 | 2.09 |
09:45 ET | 3786 | 2.078 |
09:48 ET | 1000 | 2.075 |
09:50 ET | 1503 | 2.075 |
09:52 ET | 5959 | 2.08 |
09:54 ET | 3233 | 2.075 |
09:56 ET | 858 | 2.075 |
09:57 ET | 2222 | 2.085 |
09:59 ET | 100 | 2.0899 |
10:01 ET | 3300 | 2.0764 |
10:03 ET | 200 | 2.075 |
10:06 ET | 5941 | 2.0793 |
10:08 ET | 896 | 2.08 |
10:10 ET | 1389 | 2.075 |
10:12 ET | 2200 | 2.075 |
10:14 ET | 3897 | 2.08 |
10:15 ET | 2873 | 2.075 |
10:17 ET | 4800 | 2.075 |
10:19 ET | 1820 | 2.0799 |
10:21 ET | 800 | 2.075 |
10:24 ET | 9251 | 2.065 |
10:26 ET | 10267 | 2.0601 |
10:28 ET | 100 | 2.07 |
10:30 ET | 300 | 2.065 |
10:32 ET | 18968 | 2.07 |
10:33 ET | 2096 | 2.075 |
10:35 ET | 500 | 2.075 |
10:37 ET | 1795 | 2.0792 |
10:39 ET | 2582 | 2.065 |
10:42 ET | 1200 | 2.065 |
10:44 ET | 5623 | 2.06 |
10:46 ET | 700 | 2.065 |
10:48 ET | 1500 | 2.065 |
10:50 ET | 200 | 2.065 |
10:51 ET | 1270 | 2.06 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ventyx Biosciences Inc | 149.1M | -0.7x | --- |
Acumen Pharmaceuticals Inc | 150.2M | -2.2x | --- |
PDS Biotechnology Corp | 151.3M | -3.4x | --- |
Immunic Inc | 143.2M | -1.1x | --- |
Context Therapeutics Inc | 141.7M | -1.8x | --- |
Inovio Pharmaceuticals Inc | 147.0M | -1.1x | --- |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $149.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.79 |
Book Value | $4.12 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.